Biomedical Chromatography最新文献

In this study, an online antioxidant assay based on HPLC-ABTS was mainly developed for screening the antioxidants of flavonoids from Astragali Radix (AR), and comparing the antioxidant capacity between traditional decoction pieces (TDP) of AR and cell wall-broken decoction pieces (CDP) of AR. The experimental results showed that the overall antioxidant capacity of CDP of AR was about twice as much as that of TDP of AR, which was specifically expressed as the antioxidant capacity of the screened antioxidants extracted from CDP was equivalent to 1.9-5.1 times that of those extracted from TDP, and three antioxidants were successfully screened, which were calycosin-7-O-β-D-glucoside, calycosin, and formononetin. The method established in this study is characterized by high efficiency and accuracy, which can simultaneously accomplish the screening of antioxidant components and the comparison of antioxidant capacity between samples, and provides a new method for the quality evaluation of AR from the perspective of antioxidant activity.

The traditional Chinese medicine (TCM) formula, gegen-huangqi (GH) decoction, has been employed for over 200 years, notably for its therapeutic effects in treating conditions such as atherosclerosis and diabetes mellitus. Despite its long-standing use, comprehensive studies on the chemical constituents of GH and their in vivo pharmacokinetics (PK) remain limited. This study aimed to profile the bioactive compounds present in GH decoction and to explore their PK characteristics using HPLC-Q-TOF-MS/MS. Furthermore, a robust and validated analytical method was developed and applied to assess the PK of 11 plasma compounds using HPLC-QQQ-MS/MS. In total, 79 components were identified within the GH decoction. Pharmacokinetic analysis revealed distinct absorption and elimination profiles for compounds such as puerarin, daidzin, genistin, calycosin-7-O-β-D-glucoside, and ononin, which exhibited profiles of quick absorption and excretion. Conversely, compounds such as daidzein, formononetin, genistein, astragaloside II, astragaloside IV, and calycosin showed more complex in vivo metabolic patterns, leading to multipeak concentration-time curves. All compounds, except astragalosides II and IV, were found to undergo significant hepatic clearance. These findings provide valuable insights into the pharmacokinetic behavior of GH decoction, which lays the foundation for further quality control, pharmacological exploration, and potential clinical application of this traditional remedy.

Ledipasvir in combination with sofosbuvir approved by regulatory bodies used to treat chronic hepatitis C. The present work investigates the design and development of a new, quick, green, and selective UPLC (ultra-performance liquid chromatography) approach to concurrently quantify sofosbuvir and ledipasvir. Optimization with Box-Behnken design paired the green analytical method and quality by design-based risk assessment. A mobile phase of 65%:35% ethanol by volume and phosphate buffer (15 mM; pH 3.0) was used, with a flow rate of 0.28 mL per minute, to achieve the best chromatographic separation. With linearities ranging from 20 to 100, 4.5-22.5 μg/mL, and R² values of 0.9999 and 0.9997, respectively, the established UPLC-PDA technique proved sensitive and specific for sofosbuvir and ledipasvir. The stability-indicating test findings demonstrate the degradation under the relevant stress conditions. The most environmentally friendly results were found when the level of environmental sustainability was evaluated using four advanced metrics: GAPI, AES, AMGS, and AGREE. Based on the findings, we came to the conclusion that the UPLC technique that was developed would be effective for the concurrent analysis of sofosbuvir and ledipasvir in tablet medication.

A simple, accurate, and robust reverse-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the quantification of Baclofen in rat plasma. The method demonstrated high degree of linearity (r² = 0.9936) across a concentration range of 10-50 μg/mL. Precision, accuracy, limit of detection (LOD), limit of quantification (LOQ), and robustness were evaluated according to ICH guidelines. The LOD and LOQ were found to be 0.076197 and 0.23090 μg/mL, respectively. This method provides an efficient approach for Baclofen quantification in plasma, making it suitable for pharmacokinetic and bioavailability studies. The novelty of this study lies in its optimization for routine use in laboratories, ensuring reproducibility with minimal variations across different conditions and analysts.

The chiral compounds may be biomarker candidates in human metabolism, which indicates the health status of humans. There are many applications in LC/MS that show that chiral small molecules are promising biomarkers for human diseases. Both clinical and commercial analyses of chiral metabolites are necessary due to the enantiomeric ratios of chiral molecules in biological samples may show both human health status and diseases. This review provides current and advanced LC/MS techniques for the separation and analysis of chiral molecules as disease biomarkers. In particular, sample preparation and chromatographic analysis of potential chiral biomarkers in biological samples are presented. The preparation and applications of several chiral columns used in enantiomeric separation of chiral metabolites/biomarkers by advanced LC/MS techniques are discussed. The improvement of these analyses will enable both the discovery of new chiral biomarkers and the prognosis of human diseases.

The Lingguizhugan decoction (LGZGD) is a promising traditional Chinese medicine for the treatment of gestational diabetes mellitus (GDM). However, its bioactive compounds and therapeutic mechanisms remain unknown. The main chemical composition of LGZGD was analyzed by high-performance liquid chromatography-mass spectrometry (HPLC-MS). Furthermore, the underlying mechanisms of LGZGD against GDM were elucidated through network pharmacology and molecular docking. The therapeutic efficacy and targets of LGZGD were further confirmed via an in vitro GDM model (high glucose [HG]-treated HTR-8/SVneo cells). Four compounds of LGZGD, namely, cinnamaldehyde, glycyrrhizic acid, 2-atractylenolide, and pachymic acid, were detected. A total of 26 targets for LGZGD treating GDM were obtained, which were mainly involved in oxidative stress and the PI3K-AKT signaling pathway. The protein-protein interaction (PPI) network unveiled that AKT1, TLR4, TP53, and NOS3 were hub therapeutic targets. Molecular docking showed that these targets had strong affinity with key compounds. In vitro experiments confirmed that LGZGD treatment promoted HG-induced cell viability, migration, and invasion ability while inhibited the apoptosis rate and oxidative stress. Mechanically, western blot revealed that LGZGD may protect HG-treated cells by activating the PI3K-AKT pathway and suppressing TLR4 expression. Our study preliminarily explored the mechanism of LGZGD in GDM treatment, providing a scientific basis for the clinical application of LGZGD.